44.30
price up icon1.56%   0.68
after-market 시간 외 거래: 44.46 0.16 +0.36%
loading
전일 마감가:
$43.62
열려 있는:
$43.6
하루 거래량:
3.07M
Relative Volume:
1.06
시가총액:
$11.60B
수익:
$2.17B
순이익/손실:
$521.27M
주가수익비율:
25.03
EPS:
1.77
순현금흐름:
$633.79M
1주 성능:
+1.77%
1개월 성능:
+3.31%
6개월 성능:
+30.52%
1년 성능:
+100.00%
1일 변동 폭
Value
$43.45
$44.43
1주일 범위
Value
$42.66
$44.48
52주 변동 폭
Value
$21.82
$49.62

Exelixis Inc Stock (EXEL) Company Profile

Name
명칭
Exelixis Inc
Name
전화
(650) 837-7000
Name
주소
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Name
직원
1,147
Name
트위터
@exelixisinc
Name
다음 수익 날짜
2025-02-11
Name
최신 SEC 제출 서류
Name
EXEL's Discussions on Twitter

EXEL을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
EXEL
Exelixis Inc
44.30 11.60B 2.17B 521.27M 633.79M 1.77
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Exelixis Inc Stock (EXEL) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-02-24 다운그레이드 Wells Fargo Overweight → Equal Weight
2025-01-27 업그레이드 Morgan Stanley Equal-Weight → Overweight
2025-01-24 다운그레이드 Oppenheimer Outperform → Perform
2024-12-20 다운그레이드 BMO Capital Markets Outperform → Market Perform
2024-12-17 다운그레이드 BofA Securities Buy → Neutral
2024-10-16 재확인 RBC Capital Mkts Outperform
2024-09-19 개시 UBS Neutral
2024-04-11 다운그레이드 Barclays Overweight → Equal Weight
2023-12-19 개시 BTIG Research Buy
2023-12-15 개시 Citigroup Buy
2023-09-26 개시 H.C. Wainwright Buy
2023-08-22 재확인 Oppenheimer Outperform
2023-08-08 개시 SVB Securities Market Perform
2023-07-11 재개 Morgan Stanley Equal-Weight
2023-05-10 재개 Piper Sandler Overweight
2023-03-09 개시 Wells Fargo Overweight
2023-01-26 개시 Credit Suisse Outperform
2022-10-18 개시 JMP Securities Mkt Outperform
2022-06-24 개시 BMO Capital Markets Outperform
2021-11-19 개시 Piper Sandler Overweight
2021-11-03 재개 Jefferies Buy
2021-10-07 개시 Jefferies Buy
2021-08-06 재확인 H.C. Wainwright Buy
2021-06-15 개시 H.C. Wainwright Buy
2021-05-18 재개 Goldman Sell
2021-03-31 개시 Credit Suisse Outperform
2021-03-12 개시 Wolfe Research Outperform
2020-03-04 개시 Barclays Overweight
2020-01-13 개시 SunTrust Buy
2019-11-13 개시 BofA/Merrill Buy
2019-03-18 업그레이드 Morgan Stanley Underweight → Equal-Weight
2018-09-17 개시 Goldman Neutral
2018-09-10 개시 Morgan Stanley Underweight
2018-05-11 재확인 Needham Buy
2017-10-17 재확인 Needham Buy
2017-10-17 재확인 RBC Capital Mkts Outperform
2017-10-16 재확인 SunTrust Buy
2017-09-22 다운그레이드 Leerink Partners Outperform → Mkt Perform
2017-09-15 개시 RBC Capital Mkts Outperform
2017-09-12 재확인 Needham Buy
2017-07-14 개시 SunTrust Buy
2017-03-31 개시 Needham Buy
2017-03-16 개시 Oppenheimer Perform
2017-02-28 다운그레이드 Stifel Buy → Hold
2016-11-03 개시 Deutsche Bank Buy
2016-10-10 업그레이드 Piper Jaffray Neutral → Overweight
2016-09-15 재확인 Stifel Buy
모두보기

Exelixis Inc 주식(EXEL)의 최신 뉴스

pulisher
Jun 18, 2025

Here's Why Exelixis (EXEL) is a Strong Value Stock - Yahoo Finance

Jun 18, 2025
pulisher
Jun 14, 2025

How to Take Advantage of moves in (EXEL) - news.stocktradersdaily.com

Jun 14, 2025
pulisher
Jun 14, 2025

Exelixis’s SWOT analysis: cabozantinib’s strength, zanzalintinib’s potential drive stock outlook - Investing.com Canada

Jun 14, 2025
pulisher
Jun 13, 2025

Zacks.com featured highlights include Flex, CVS Health, Urban Outfitters and Exelixis - Yahoo Finance

Jun 13, 2025
pulisher
Jun 12, 2025

EXEL: HC Wainwright & Co. Raises Price Target to $47.00 | EXEL S - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Exelixis stock maintains buy rating at H.C. Wainwright on promising data - Investing.com Canada

Jun 12, 2025
pulisher
Jun 12, 2025

Why Is Exelixis (EXEL) Down 7.2% Since Last Earnings Report? - Yahoo Finance

Jun 12, 2025
pulisher
Jun 12, 2025

Exelixis, Inc.'s (NASDAQ:EXEL) Stock's On An Uptrend: Are Strong Financials Guiding The Market? - simplywall.st

Jun 12, 2025
pulisher
Jun 12, 2025

EXEL: HC Wainwright & Co. Raises Price Target to $47.00 | EXEL Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Exelixis (EXEL) Stock Target Boosted by H.C. Wainwright | EXEL S - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Promising Clinical Data and Favorable Safety Profile Drive Buy Rating for Exelixis - TipRanks

Jun 12, 2025
pulisher
Jun 12, 2025

Exelixis (EXEL) Stock Target Boosted by H.C. Wainwright | EXEL Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 10, 2025

Indexes Rise But Growth Plays Hit; Quanta Services, Exelixis, Google In Focus - Investor's Business Daily

Jun 10, 2025
pulisher
Jun 09, 2025

Kalkine: Exelixis Joins Momentum Wave Ahead of Russell 1000 Rebalance - Kalkine Media

Jun 09, 2025
pulisher
Jun 09, 2025

BofA Hikes Exelixis, Inc. (EXEL) Target Amid CRC Caution - MSN

Jun 09, 2025
pulisher
Jun 09, 2025

3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL) - Yahoo Finance

Jun 09, 2025
pulisher
Jun 09, 2025

Exelixis, Inc. (EXEL) Stock Analysis: A Biotech Powerhouse with Robust Revenue Growth - DirectorsTalk Interviews

Jun 09, 2025
pulisher
Jun 09, 2025

Exelixis, Inc. (NASDAQ:EXEL) Stock Holdings Increased by GAMMA Investing LLC - Defense World

Jun 09, 2025
pulisher
Jun 07, 2025

Bank of America Forecasts Strong Price Appreciation for Exelixis (NASDAQ:EXEL) Stock - Defense World

Jun 07, 2025
pulisher
Jun 07, 2025

Brokerages Set Exelixis, Inc. (NASDAQ:EXEL) Price Target at $38.94 - Defense World

Jun 07, 2025
pulisher
Jun 07, 2025

Zacks Research Has Bullish Forecast for Exelixis Q2 Earnings - Defense World

Jun 07, 2025
pulisher
Jun 06, 2025

Exelixis Escapes Cancer Drug Invalidity Bid At PTAB - Law360

Jun 06, 2025
pulisher
Jun 06, 2025

Are You Looking for a Top Momentum Pick? Why Exelixis (EXEL) is a Great Choice - Yahoo Finance

Jun 06, 2025
pulisher
Jun 05, 2025

Analyst Expectations For Exelixis's Future - Benzinga

Jun 05, 2025
pulisher
Jun 05, 2025

Exelixis (EXEL) Sees Price Target Raised by B of A Securities | - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

BofA Adjusts Price Target for Exelixis (EXEL) Amid Critical Pipe - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Director Jack Wyszomierski Sells 7,535 Shares of Exelixis Inc (E - GuruFocus

Jun 05, 2025
pulisher
Jun 04, 2025

Director Jack Wyszomierski Sells 7,535 Shares of Exelixis Inc (EXEL) - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Exelixis at Jefferies Conference: Strategic Moves for Growth By Investing.com - Investing.com Canada

Jun 04, 2025
pulisher
Jun 04, 2025

Exelixis Stock Surges 28% YTD: Should You Buy Now or Sell? - sharewise

Jun 04, 2025
pulisher
Jun 04, 2025

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term - sharewise

Jun 04, 2025
pulisher
Jun 04, 2025

Transcript : Exelixis, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 07 - MarketScreener

Jun 04, 2025
pulisher
Jun 03, 2025

Exelixis Stock Surges 28% YTD: Should You Buy Now Or Sell? - Barchart.com

Jun 03, 2025
pulisher
Jun 03, 2025

Stifel maintains hold rating on Exelixis stock, sets $38 target - Investing.com

Jun 03, 2025
pulisher
Jun 03, 2025

Exelixis at 45th Annual William Blair Conference: Oncology Ambitions - Investing.com Australia

Jun 03, 2025
pulisher
Jun 03, 2025

Transcript : Exelixis, Inc. Presents at 45th Annual William Blair Growth Stock Conference, Jun-03-2025 10 - MarketScreener

Jun 03, 2025
pulisher
Jun 02, 2025

Here's Why Exelixis (EXEL) is a Strong Growth Stock - Yahoo Finance

Jun 02, 2025
pulisher
Jun 02, 2025

Exelixis, Inc. (EXEL) Stock Analysis: Navigating Growth in the Biotech Space with Robust Revenue Momentum - DirectorsTalk Interviews

Jun 02, 2025
pulisher
May 31, 2025

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025 - Business Wire

May 31, 2025
pulisher
May 30, 2025

2 Top Stocks to Buy With Less Than $100 - The Globe and Mail

May 30, 2025
pulisher
May 28, 2025

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term - Yahoo Finance

May 28, 2025
pulisher
May 27, 2025

Transcript : Exelixis, Inc. Presents at TD Cowen's 6th Annual Oncology Innovation Summit, May-27-2025 02 - marketscreener.com

May 27, 2025
pulisher
May 27, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Decreases Stake in Exelixis, Inc. (NASDAQ:EXEL) - Defense World

May 27, 2025
pulisher
May 26, 2025

Exelixis, Inc. (EXEL) Stock Analysis: A Biotech Powerhouse with Promising Growth Potential - DirectorsTalk Interviews

May 26, 2025
pulisher
May 25, 2025

EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort - MSN

May 25, 2025
pulisher
May 25, 2025

Exelixis’s SWOT analysis: stock poised for growth amid oncology pipeline progress By Investing.com - Investing.com South Africa

May 25, 2025
pulisher
May 25, 2025

Exelixis’s SWOT analysis: stock poised for growth amid oncology pipeline progress - Investing.com Australia

May 25, 2025
pulisher
May 25, 2025

Deutsche Bank AG Has $1.54 Million Stake in Exelixis, Inc. (NASDAQ:EXEL) - Defense World

May 25, 2025

Exelixis Inc (EXEL) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Exelixis Inc 주식 (EXEL) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
WYSZOMIERSKI JACK L
Director
Jun 03 '25
Sale
43.09
7,535
324,683
358,882
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
자본화:     |  볼륨(24시간):